Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|6|8|645-657

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.6, Iss.8, 2006-12, pp. : 645-657

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resistance to Imatinib: Mechanisms and Management

By Deininger Michael  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 3, Iss. 6, 2005-11 ,pp. : 757-768

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Molecularly targeted therapy in myeloid leukaemias

By Craddock Charles  

Clinical Medicine, Vol. 7, Iss. 6, 2007-12 ,pp. : 632-635

Royal College Of Physicians

Access to resources Recommend Favorite

Molecularly Targeted Therapy for Gastrointestinal Cancer

By  

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 171-193

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

By  

Current Molecular Pharmacology, Vol. 3, Iss. 1, 2010-01 ,pp. : 37-52

Bentham Science Publishers

Access to resources Recommend Favorite

Value of imatinib uncertain in CML

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 479, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite